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Background: Oxidative stresses including cigarette smoking
are implicated in the pathogenesis of cerebrovascular
diseases, which are associated with pneumonia because of
frequent aspiration. Haem oxygenase-1 (HO-1) acts in
cytoprotection against oxidants, provides anti-inflammatory
effects, and inhibits atherogenesis. A (GT)n dinucleotide
repeat in the human HO-1 promoter modulates HO-1 gene
expression and shows length polymorphism, which is
grouped into three classes: class S (,27 repeats), class M
(>27, ,33 repeats), and class L (>33 repeats) alleles.
Objective: To investigate the correlation between the HO-1
gene polymorphism and development of pneumonia in
elderly Japanese.
Methods: The length of the (GT)n repeats was analysed in
200 elderly patients with pneumonia and 200 control
subjects. The association of the HO-1 gene polymorphism
with risk of pneumonia was estimated by logistic regression.
Results: The proportion of allele frequencies in class L, and
the proportion of genotypic frequencies in the L-allele carriers
(L/L, L/M, and L/S), was significantly higher in patients with
pneumonia than in controls (20% v 10% in class L, and 34% v
18% in L-allele carriers). After adjustment for potentially
confounding factors, both cerebrovascular disorders and
HO-1 gene L-allele carriers were significant and independent
risk factors for pneumonia. The adjusted odds ratio for L-
allele carriers v non-L-allele carrier was 2.1 (95% confidence
interval, 1.2 to 3.6).
Conclusions: The large size of a (GT)n repeat in the HO-1
gene promoter may be associated with susceptibility to
pneumonia in the older Japanese population.
P
neumonia is not only a common infection in older
people, it is also the most common cause of death from
nosocomial infection in the Japanese population.1
Disorders of the central nervous system are more likely to
develop in the elderly, and pneumonia has been estimated to
occur in about one third of patients with stroke.2
Cerebrovascular disease is associated with a high incidence
of pneumonia owing to frequent aspiration.3 As well as
factors including diabetes mellitus, hyperlipidaemia, and
hypertension, oxidative stresses such as cigarette smoking are
also associated with the pathogenesis of cerebrovascular
disease.4 Genetic factors affecting antioxidants may be
involved in the susceptibility to atherosclerosis of the cerebral
arteries and the subsequent development of pneumonia in
the elderly. Although the antioxidant enzymes inhibit the
formation of atherosclerosis,5 the roles of reduced expression
of these enzymes on the development of pneumonia in
elderly people are still uncertain.
Haem oxygenase (HO) oxidatively degrades haem to
biliverdin, which is subsequently reduced to bilirubin, an
efficient scavenger of reactive oxygen species (ROS), by
biliverdin reductase.6 HO-1, an inducible form of HO—and
also a constitutive form of HO, including HO-2—provides
cellular protection against haem mediated and non-haem-
mediated oxidant injury.6 HO-1 is thought to be an essential
component in protection against various ROS.
A (GT)n repeat in the 59 flanking region of the human HO-1
gene is polymorphic,7 and modulates human HO-1 gene
transcription by thermal stress8 and hydrogen peroxide.7 The
size of the (GT)n repeat in the HO-1 gene is associated with
the antiapoptotic effects of HO-1 in lymphoblastoid cell
lines.9 We have shown that the size of the (GT)n repeat in the
HO-1 gene is associated with susceptibility to chronic
pulmonary emphysema (CPE)7 and lung adenocarcinoma,10
and with longevity11 in Japanese populations. This HO-1 gene
polymorphism is also associated with coronary artery disease,
one of vascular diseases related to ROS.12 However, the
association between the size of the (GT)n repeat in the HO-1
gene and the development of pneumonia in older populations
is still uncertain.
In the present study, we screened allelic frequencies of the
(GT)n repeats in the HO-1 gene promoter in elderly people
with and without pneumonia, and examined the association
between the risk of senile pneumonia and length of the (GT)n
repeats.
METHODS
Clinical protocol and patient characteristics
We studied 200 elderly patients with pneumonia and 200
elderly control subjects without pneumonia, attending the
departments of internal medicine in six hospitals in Miyagi
prefecture. The hospitals were a university hospital, a Red
Cross hospital, three public general hospitals, and a
municipal hospital. All participants were Japanese and aged
65 and older. To evaluate whether HO-1 genotypes are
associated with the development of pneumonia in elderly
Japanese people, we selected the subjects with a performance
status of 2 or better13 and in a stable state as potential
participants, because those with too low a performance status
ran a greater risk of infectious disease, which might mask the
preventive effect of any genetic factors. Patients were given a
score of 0 if they were fully active and asymptomatic, 1 if they
were symptomatic but fully ambulatory, 2 if they were
Abbreviations: COPD, chronic obstructive pulmonary disease; CPE,
chronic pulmonary emphysema; HO, haem oxygenase; HO-1, inducible
haem oxygenase; ROS, reactive oxygen species; TNF, tumour necrosis
factor
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symptomatic and confined to bed or chair for less than 50%
of their waking hour, 3 if they were symptomatic and
confined to bed or chair for more than 50% of their waking
hours, and 4 if they were completely bedridden. The study
was approved by the Tohoku University ethics committee,
and informed consent was obtained from each subject. This
study was carried out between April 2002 and December
2004.
During the study period, 264 elderly patients with
pneumonia were identified. Pneumonia was defined as
pulmonary infiltrate on chest radiograph, cough, and a
temperature higher than 38.0 C˚.3 All patients with pneumo-
nia had the features of pulmonary infiltrate on chest
radiographs, cough, and a temperature above 38.0 C˚. The
patients were enrolled consecutively. Among them, we
selected for the case group those with a performance status
of 2 or better and in a stable state. We excluded patients who
were immunocompromised—for example, those with active
malignant disease, on renal dialysis, receiving corticosteroid
treatment, or with HIV-1 infection. Patients were also
excluded if they had obvious swallowing dysfunction,
chronic sepsis in pressure sores, venous ulcers, or an
indwelling urinary catheter. After these selections and
exclusions were applied, 200 elderly patients with pneumonia
were enrolled in the case group.
Potential control subjects were 439 elderly patients who
continued attending the departments of hospitals over the
study period and who had never had pneumonia at any time
in their life including the study period. Control subjects were
excluded if their past history relating to pneumonia were
unclear. After the same selection and exclusion criteria as in
the case group were applied, 383 control subjects were
available for frequency matching. To carry out a case–control
study, we randomly selected 200 control subjects in a
frequency matched manner from the control cohort. They
were frequency matched on age (¡5 years), sex, smoking
history, and performance status with the patients with
pneumonia. Physical characteristics, smoking history, and
complications in patients with pneumonia and control
subjects are shown in table 1.
Analysis of length variability of (GT)n repeats in HO-1
gene promoter
Genomic DNAs were extracted from leucocytes in peripheral
venous blood by conventional procedures. The 59-flanking
region containing a poly (GT)n repeat of the HO-1 gene was
amplified by polymerase chain reaction (PCR)7 11 with a
fluorescently labelled primer p1-s (59-AGAGCCTGCAGC
TTCTCAGA-39) and an unlabeled antisense primer p1-as
(59-ACAAAGTCTGGCCATAGGAC-39), which were designed
Table 1 Characteristics of the study subjects
Characteristics
Control subjects Patients with
p Value(n = 200) pneumonia (n = 200)
Age (years)* 73.8 (0.7) 75.4 (1.0) NS
Sex
Male 99 (50%) 101 (50%) NS
Female 101 (50%) 99 (50%)
Performance status
0–1 114 (57%) 108 (54%) NS
2 86 (43%) 92 (46%)
Smoking history (pack-year)* 18.2 (2.6) 19.3 (2.8) NS
Cerebrovascular disease
Yes 14 (7%) 101 (50%) ,0.0001
No 186 (93%) 99 (50%)
COPD
Yes 35 (18%) 38 (19%) NS
No 165 (82%) 162 (81%)
Congestive heart failure
Yes 17 (9%) 28 (14%) NS
No 183 (91%) 172 (86%)
Hypertension
Yes 43 (22%) 59 (30%) NS
No 157 (78%) 141 (70%)
Diabetes mellitus
Yes 21 (10%) 34 (17%) NS
No 179 (90%) 166 (83%)
Hyperlipidaemia
Yes 9 (5%) 10 (5%) NS
No 191 (95%) 190 (95%)
Values are n (%) or *mean (SD).
COPD, chronic obstructive pulmonary disease.
Table 2 Allele and genotypic frequencies of HO-1at polymorphic locus
Control subjects
(n = 200)
Patients with
pneumonia
(n = 200)
OR (95% CI) v all
other classes or
subjects p Value
Allele class
L 38 (10%) 79 (20%) 2.3 (1.5 to 3.5) ,0.0001
M 189 (47%) 159 (40%) 0.7 (0.5 to 0.9) ,0.05
S 173 (43%) 162 (40%) 0.9 (0.7 to 1.2) NS
Genotype group
L-allele carrier 36 (18%) 68 (34%) 2.3 (1.5 to 3.7) ,0.001
Non-L-allele carrier 164 (82%) 132 (66%)
CI, confidence interval; OR, odds ratio.
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according to the published sequence.7 14 The PCR was carried
out over 30 cycles of 20 seconds at 94 C˚, 10 seconds at 60 C˚,
and 20 seconds at 72 C˚. The PCR products were analysed in a
DNA sequencer (ALF express II DNA sequencer version 2.2,
Amersham Pharmacia Biotech, Piscataway, New Jersey,
USA). Each size of (GT)n repeat in the PCR product was
calculated with ALFwin fragment analysis version 1.03
(Amersham Pharmacia Biotech) using four cloned alleles as
size markers, which were already sequenced with the ABI
prism dye terminator sequencing kit (Perkin-Elmer Applied
Biosystems, Foster City, California, USA).7 The repeat
numbers of these size markers were 16, 23, 29, and 38,
respectively. The investigators of genetic analysis were
blinded with respect to the status of the subjects.
Carboxyhaemoglobin concentrations in patients with
pneumonia
Blood samples were taken from the radial artery in patients
with pneumonia on the first day of hospital admission. The
patients for the carboxyhaemoglobin analysis were all non-
smokers and consisted of five L-allele carriers and five non-L-
allele carriers (L/L genotype and S/S genotype, respectively),
who showed a similar C reactive protein concentration (15.0
to 20.0 mg/dl) and white blood cell (WBC) count (9500 to
12 500 cells/ml) at the time of analysis. The carboxyhaemo-
globin concentrations were measured with a spectrophot-
ometer (ASL System, Radiometer, Copenhagen, Denmark).15
Statistical analysis
In the analysis of HO-1 gene polymorphism in this study, the
patient and control groups were frequency matched by age,
sex, performance status, and smoking history. For statistical
analysis, age and smoking history (pack-year) between the
two groups were compared using Student’s t test, and sex,
performance status, and the frequency of the complications
between the two groups were compared using x2 tests
(table 1), as described previously in coronary artery disease.12
The proportion of allelic frequencies and genotypic frequen-
cies between the two groups were also compared using the x2
test (table 2). Factors associated with the presence of senile
pneumonia such as age, sex, performance status, smoking
status, complications, and HO-1 gene polymorphism (L-allele
carrier) were examined with multivariate analysis by logistic
regression analysis (table 3). Odds ratios (OR) and their 95%
confidence intervals (CI) were calculated to assess the
relative risk conferred by a particular genotype (L-allele
carrier), and adjusted for age, sex, performance status,
smoking history, and complications using logistic regression
as described previously (table 3).12 All the statistical analyses
were undertaken using SYSTAT (version 10.2; SYSTAT
Software, Richmond, California, USA). The values for age
and smoking history (pack-year) are reported as means (SD).
The HO-1 genotype distributions were in Hardy–Weinberg
equilibrium. Significance was accepted at p,0.05.
For statistical analysis in the study on the correlation
between carboxyhaemoglobin level and HO-1 genotype in the
patients with pneumonia, the mean values for age (year),
smoking history (pack-year), WBC number (cells/ml), C
reactive protein (mg/dl), and carboxyhaemoglobin concen-
tration (%) between the five L-allele carriers and the five
non-L-allele carriers were compared using Student’s t test
and sex using the x2 test (table 4).
RESULTS
Allele frequencies of HO-1 gene in control and
patients with pneumonia in older adults
There were between 16 and 39 (GT)n repeats in the human
HO-1 gene in the study subjects (fig 1). The distribution of
the number of (GT)n repeats was trimodal, as previously
reported, with two main peaks located at 23 and 30 GT
repeats and another peak located at 33 GT repeats.7 10 11 We
therefore divided the alleles into three subclasses, as
previously reported7: class S (,27 repeats), class M (>27
and ,33 repeats), and class L (>33 repeats) alleles.
In the control subjects, the distributions of the 400 alleles
were 173 (43%) class S, 189 (45%) class M, and 38 (10%)
class L (table 2); in the patients with pneumonia, the
distributions were 162 (40%) class S, 159 (40%) class M, and
79 (20%) class L. The proportion of allelic frequencies in class
L was significantly higher in all patients with pneumonia
(n = 79, 20%) than that in all control subjects (n = 38, 10%)
Table 3 Multivariate analysis of risk factors related to
pneumonia in older adults
Variable OR (95% CI) p Value
Haem oxygenase-1 genotype
subgroup
L-allele carriers v non-L-allele
carriers 2.1 (1.2 to 3.6)* ,0.01
Cerebrovascular disease
Yes v no 28.0 (13.3 to 58.6) ,0.0001
*OR was calculated with the non-L-allele carriers as the reference group,
and adjusted for age, gender, performance status, smoking history, and
complications.
OR was calculated with the patients without cerebrovascular disease as
the reference group, and adjusted for age, gender, performance status,
smoking history, HO-1 genotype, and complications other than
cerebrovascular disease.
CI, confidence interval; OR, odds ratio.
Table 4 Arterial blood carboxyhaemoglobin in patients with pneumonia
Patient
HO-1 Age
Sex
Smoking
history WBC CRP Arterial blood
genotype (years)* (pack-year)* (cells/ml)* (mg/dl)* Hb-CO (%)`
L-allele carrier 1 LL 71 M 0 12 300 18.3 0.57
L-allele carrier 2 LL 65 F 0 10 500 15.2 0.20
L-allele carrier 3 LL 79 F 0 9 700 15.7 0.80
L-allele carrier 4 LL 73 F 0 9 600 19.0 0.21
L-allele carrier 5 LL 76 F 0 10 020 19.4 1.20
Non-L-allele carrier 1 SS 65 M 0 12 400 18.5 1.50
Non-L-allele carrier 2 SS 77 M 0 11 000 16.3 1.20
Non-L-allele carrier 3 SS 79 F 0 10 500 19.2 1.02
Non-L-allele carrier 4 SS 65 F 0 9 900 15.6 1.10
Non-L-allele carrier 5 SS 75 F 0 9 600 19.5 0.90
*There was no significant difference in the mean value between L-allele carrier and non-L-allele carrier (p.0.7).
There was no significant difference in the ratio between L-allele carrier and non-L-allele carrier (p.0.5).
`There was a significant difference in the mean value between L-allele carrier and non-L-allele carrier (p,0.04).
CRP, C reactive protein; F, female; Hb-CO, carboxyhaemoglobin; M, male; WBC, white blood cell count.
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(p,0.0001). The odds ratio for pneumonia with L alleles v
non-L alleles (class M allele + class S allele) was 2.3 (95% CI,
1.5 to 3.5) (table 2).
Genotypic frequencies of HO-1 gene in control and
patients with pneumonia
Six genotypes (L/L, L/M, L/S, M/M, M/S, and S/S) of (GT)n
repeats in the human HO-1 gene promoter were divided into
two subgroups according to allelic subclasses: L-allele carriers
with a class L allele (L/L, L/M, L/S) and non-L-allele carriers
without a class L allele (M/M, M/S and S/S).7 The proportion
of genotypic frequencies in L-allele carriers was significantly
higher in all patients with pneumonia (n = 68, 34%) than
that in all control subjects (n = 36, 18%) (p,0.0001). The
odds ratio for patients with pneumonia with L-allele carriers
v non-L-allele carriers was 2.3 (95% CI, 1.4 to 3.7) (table 2).
Risk factors for pneumonia
On multivariate analysis, cerebrovascular disease (p,0.0001)
and HO-1 genotype (p,0.01) were significantly and inde-
pendently associated with the development of pneumonia
(table 3), when the variables were adjusted by age, sex,
performance status, smoking history, and complications
including congestive heart failure, COPD, hypertension,
diabetes mellitus, and hyperlipidaemia. The adjusted odds
ratio (95% CI) was 2.1 (1.2 to 3.6) for HO-1 genotype and 28.0
(18.3 to 58.6) for cerebrovascular disease (table 3).
Carboxyhaemoglobin concentrations in patients with
pneumonia
To show the correlation between HO-1 genotype and HO-1
activity caused by the inflammation of pneumonia, we
examined the carboxyhaemoglobin concentration in several
patients with pneumonia on their first day of hospital
admission. The subjects for carboxyhaemoglobin analysis
were five L-allele carriers and five non-L-allele carriers (L/L
genotype and S/S genotype, respectively). There were no
significant differences in age, sex, smoking history, WBC
count, and C reactive protein concentration level between
these two groups. However, the patients without the L-allele
showed significantly higher carboxyhaemoglobin levels than
those with the L-allele (1.14 (0.23)% v 0.5 (0.42)%,
respectively; p,0.04) (table 4).
DISCUSSION
In this study we analysed HO-1 gene polymorphism and
showed that the proportion of allele frequencies in class L
and the proportion of genotypic frequencies in the L-allele
carriers (L/L, L/M, and L/S) were significantly higher in
elderly people with pneumonia than in control subjects. The
proportion of subjects with cerebrovascular disease in the
pneumonia group was significantly higher than in the control
group. With multivariate analysis, HO-1 genotype and the
presence of cerebrovascular disease were significant and
independent risk factors for pneumonia. These findings
suggest that the large size of a (GT)n repeat in the HO-1
gene promoter may be associated with the development of
pneumonia in older Japanese people with cerebral infarction.
Disorders of the central nervous system are more likely to
develop in the elderly, and pneumonia has been estimated to
occur in about one third of patients with stroke.2 Basal
ganglia infarction is associated with a high incidence of
pneumonia owing to frequent aspiration3 resulting from the
reduction in the cough and swallowing reflexes.16 In fact, in
the present study, half these older patients with pneumonia
also had cerebrovascular disease.
Oxidative stress such as cigarette smoking4 is one of the
important risk factors for cerebrovascular diseases, including
basal ganglia infarction. Various ROS including superoxide
and hydrogen peroxide induce lipid peroxide formation,
which is a key process in atherosclerotic plaques in
hypercholesterolaemia.17 ROS are also involved in the brain
tissue damage in stroke.18 On the other hand, antioxidant
systems such as glutathione, superoxide dismutase, and HO
are suggested to protect the vascular disease caused by ROS.19
The initial degradation of haem by microsomal HO involves
the liberation of iron and CO and the formation of biliverdin,
which is subsequently reduced to bilirubin by cytosolic
biliverdin reductase.6 Higher intracellular HO-1 activity may
increase the content of bilirubin, which is an efficient
scavenger of ROS,6 and a natural inhibitor of intimal
hyperplasia after balloon injury.20 In fact, Ishikawa et al.
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Figure 1 Frequency distribution of the number of (GT)n repeats in control subjects (n = 400 alleles) and patients with pneumonia (n = 400 alleles).
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reported inhibitory effects of HO-1 on the atherogenesis in
hyperlipidaemic rabbits.21 Enhanced endothelial cell injury
caused by oxidative stress was observed in a human case of
HO-1 deficiency.22 Reduced expression of HO-1 might be
partly associated with the development of stroke and
subsequent pneumonia.
A (GT)n dinucleotide repeat in the 59-flanking region of
human HO-1 gene shows length polymorphism.7 We pre-
viously reported the influence of the number of the (GT)n
repeats on the inducibility of the HO-1 gene promoter under
oxidative stimulus by transient transfection assay in human
cell lines. The promoter activity of HO-1 is modulated by the
length variability of the (GT)n repeats, and large (GT)n
repeats have a potent inhibitory activity on H2O2 induced
gene expression of HO-1.7 Furthermore, Epstein-Barr virus
transformed lymphoblastoid cell lines were established from
smokers with class L alleles (L/L) and with class S (S/S).
When treated with H2O2, lymphoblastoid cells with the L/L
genotype showed lower viability than those with the S/S
genotype.9 The GT dinucleotide repeat polymorphism has
emerged as a potent genetic risk factor in various diseases,
including vascular diseases such as coronary arteriosclerosis12
and restenosis after balloon angioplasty.23 These findings are
consistent with the view that tissues of the non-L allele
carrier could employ the antioxidant activity of HO-1 to a
greater extent than that of the L-allele carrier when exposed
to reactive oxygen species.10 Large (GT)n repeats may affect
the protective function against oxidant induced vascular
endothelial injury and arteriosclerosis through the inhibition
of HO-1 expression.
The results of our study suggest that the HO-1 genotype is
associated with susceptibility to pneumonia independently of
cerebrovascular disease. Senile pneumonia is characterised by
a high likelihood of aspiration pneumonia.16 The severity of
aspiration pneumonia is associated with the lung inflamma-
tion mediated by cytokines such as tumour necrosis factor a
(TNFa).24 On the other hand, it was reported that over-
expression of the HO-1 gene attenuated inflammation and
decreased apoptosis of bronchial epithelial cells in a murine
model of lung inflammation induced by Pseudomonas aerugi-
nosa.25 Furthermore, overexpression of the HO-1 gene could
reduce TNFa mediated apoptotic cell death in human
endothelial cells.26 These findings suggest that HO-1 gene
expression could be associated with the progress of aspiration
pneumonia, and that reduced expression of the HO-1 gene in
elderly L-allele carriers might allow the development of
pneumonia independently of cerebrovascular disease.
To examine the association between HO-1 genotype and
HO-1 activity in the pneumonia, we evaluated the carbox-
yhaemoglobin level in L-allele carriers and non-L-allele
carriers with pneumonia. As a result, even after adjustment
for the peripheral WBC count and C reactive protein level,
patients without the L-allele showed higher carboxyhaemo-
globin levels than those with the L-allele. Carbon monoxide
(CO) is produced endogenously by HO and combines
haemoglobin to form carboxyhaemoglobin complex.
Therefore, the carboxyhaemoglobin concentration in the
subject is a good marker of endogenous HO activity.27
Furthermore, it has been reported that HO-1 is strongly
induced in patients with bacterial infection.28 We have
already shown that arterial carboxyhaemoglobin increases
at the onset of pneumonia in untreated patients returns to
baseline on recovery after treatments.15 We also showed that
an increase in arterial carboxyhaemoglobin in pneumonia
would be caused by carbon monoxide production in
pulmonary inflammation, and that the arterial carboxyhae-
moglobin is significantly correlated with disease severity in
patients with bacterial pneumonia.29 A study of lymphoblas-
toid cell lines by Hirai et al showed that mRNA level and
activity of HO-1 were significantly higher in lymphoblastoid
cells with the S/S genotype than in those with the L/L
genotype after oxidant stimulation.9 Therefore, analysis of the
carboxyhaemoglobin level in pneumonia according to HO-1
genotype would clarify the association between the HO-1
genotype and HO-1 activity—that is, the HO-1 protein level,
resulting from pneumonia. These findings suggest that HO-1
induction might be associated with the HO-1 genotype
(S.M.L).
In contrast to arterial blood carboxyhaemoglobin concen-
trations, we did not measure HO-1 activity in patients with
pneumonia at the onset. However, we obtained new blood
samples from eight people in the control group and seven in
the pneumonia group after recovery from pneumonia, and
analysed the serum HO-1 protein levels using enzyme linked
immunosorbent assay methods as previously described.30
There was no significant difference between these two
groups when they were in good physical condition (2.6
(1.2) v 2.4 (1.0) ng/ml, p.0.2). These values were compatible
with the results from a previous report.30 Because the HO-1
gene is inducible by inflammation or oxidative stress, the
baseline expression of the this gene should be low regardless
of the HO-1 genotype, which was demonstrated in lympho-
blastoid cell by Hirai et al.9 Further studies are needed to
clarify the relation between HO-1 activity and the HO-1
genotype at the onset of pneumonia.
Conclusions
This is the first study to show that the 59-flanking
polymorphism in the HO-1 gene is associated with the
development of pneumonia in an older Japanese population
with basal ganglia infarction. Increased susceptibility to
developing pneumonia may be associated with sclerosis in
the cerebral arteries.
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